The alternative pathway of complement in disease: opportunities for therapeutic targeting.
about
Complement in the Homeostatic and Ischemic BrainMolecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"?A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritisVariability and action mechanism of a family of anticomplement proteins in Ixodes ricinusReduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activationAge-related macular degeneration--emerging pathogenetic and therapeutic concepts.Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degenerationExperimental membranous nephropathy reduxInhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice.Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association?The alternative complement pathway revisited.Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopyA novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.The role of the complement system in CNS inflammatory diseases.Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice.Neonatal porcine Sertoli cells inhibit human natural antibody-mediated lysis.Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus.Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the "holy grail".Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner.Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice.Inflammation and microvasculopathy in renal ischemia reperfusion injury.Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.Origins of chemical biodefence
P2860
Q26796057-F35227F2-1E07-4040-A7CC-EB3C53A977A6Q26825724-5FF58F6B-9ACE-4374-8FB1-50440ADC2761Q27645256-C68027D1-AF04-4C6A-8A31-D88469303662Q28471851-7FBBE1F0-A89E-4856-8FF9-2E6FAC5B95C6Q33250260-46B455F5-3B53-4A1F-9E59-BCCFF0DFF8B5Q33263472-EEEDCF5A-50E5-4553-B927-7896241C01DEQ33880198-B78E67AF-E209-48F6-A414-0186D44D115FQ34066021-0EA8B398-7531-429B-8C18-771C306AFCCCQ34248969-7A65D5F0-5275-4C39-8C0D-9B4EE27FB5DAQ35790611-03779304-FC02-42A8-88EE-ADB737B84793Q36401237-7D544701-BA26-4F40-8214-A41CDB68E12FQ36698228-A1AD1F28-964F-45F5-8A12-5AEA6C0395DEQ36735756-AE5E10DD-63B1-4EF8-A774-7729E0B9DD2FQ37141297-1137BFF4-1454-4B35-81AE-954346147A51Q37323288-C67DB218-62B2-4AA0-BAE8-CB4E3087688CQ37343678-2DBFD66E-9CB7-4F89-92C7-F3AA5B635163Q37434667-AB3AD31B-3AB0-4C8E-838C-E5E2DC6E5DCCQ37486139-90A812F1-DC0D-4D8A-9991-D83BD2CF66E1Q37607698-95900B89-209F-4766-9A2D-0EF562675317Q37650971-F46F3CCE-6490-4FF7-B30C-4F38BCAC0BB1Q37754532-E7542BB4-A36C-47D0-B744-F271F5D2FAFEQ37963808-F2417D50-418F-440F-B3C6-426ECAE1699EQ38331710-750B34CD-EB31-4351-A633-808A7A354A2BQ39951314-FA48BA60-AAF1-472F-A75B-F914EE8279ADQ41459773-F38B9C47-633D-466B-AF2E-67A8B657C5C5Q41769162-4A6754F4-361E-4330-ABFB-D3ED530E7240Q41771843-6E0C8931-4563-4407-80EE-4C40D145239FQ42560799-B39BD66D-4EEB-494A-8910-33113088270AQ46433084-E150C942-6A5A-4559-8369-37531B47F5C6Q74441738-19E77825-F3E2-410D-B3A1-EE21C15CF410
P2860
The alternative pathway of complement in disease: opportunities for therapeutic targeting.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The alternative pathway of com ...... ies for therapeutic targeting.
@ast
The alternative pathway of com ...... ies for therapeutic targeting.
@en
type
label
The alternative pathway of com ...... ies for therapeutic targeting.
@ast
The alternative pathway of com ...... ies for therapeutic targeting.
@en
prefLabel
The alternative pathway of com ...... ies for therapeutic targeting.
@ast
The alternative pathway of com ...... ies for therapeutic targeting.
@en
P1433
P1476
The alternative pathway of com ...... ies for therapeutic targeting.
@en
P2093
Joshua M Thurman
V Michael Holers
P304
P356
10.1016/J.MOLIMM.2004.03.012
P577
2004-06-01T00:00:00Z